Our group has previously reported the efficacy of different CHK1/CHK2 inhibitors as a single agent and in combinations in primary ALL samples [43], suggesting that this approach might be amenable for the treatment of ALL in a clinical setting. Here, CHEK2 is linked to acute lymphoblastic leukemia.